Abstract

A BRIEF REVIEW ON FORMULATION AND OPTIMIZATION OF PULSATILE DRUG DELIVERY SYSTEM OF ANTI-HYPERTENSIVE DRUG

Rakesh Gowda T. S.*, Dr. Jesindha Beyatricks and Dr. S. N. Sriharsha

ABSTRACT

The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPAR γ) activating properties, and to have a favourable metabolic profile. Current discussion is whether the addition of small doses of hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care.

Keywords: Irbesartan, hypertension, angiotensin II.